6483.Two
6483.TWO is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.
Business. 6483.TWO is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6483.TWO is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biotech products.
The company's capital structure is characterized by a high proportion of equity, with total equity of TWD 157,838,000 and total liabilities of TWD 26,097,000, resulting in a debt-to-equity ratio of 0.07. The liquidity position is strong, as evidenced by a current ratio of 9.74 and cash and equivalents of TWD 133,851,000. The price-to-book ratio of 5.46 suggests that the market is valuing the company's equity at a premium relative to its book value.
Profitability metrics indicate significant challenges, with a net loss of TWD 101,510,000 and an operating loss of TWD 104,596,000. The return on equity of -64.31% and return on assets of -55.19% highlight the company's inability to generate returns from its equity and asset base. These figures are notably worse than the industry median, indicating underperformance in profitability and returns.
The company's revenue is not segmented by geographic region or product line in the provided data, making it difficult to assess geographic exposure or revenue concentration. However, the absence of disclosed segments suggests that the company may have a concentrated revenue base, which could pose a concentration risk if not diversified.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided. The operating cash flow of -TWD 96,009,000 and free cash flow of -TWD 94,371,000 indicate a lack of positive cash generation, which could hinder future growth initiatives. The capital expenditure of -TWD 949,000 suggests minimal investment in long-term assets, which may limit the company's ability to scale operations.
Risk factors include a low liquidity risk and a low dilution risk, as no immediate filing-based liquidity or dilution flags were detected. The company's low debt levels and strong cash position reduce the likelihood of liquidity stress. However, the significant net loss and negative returns suggest that the company may need to raise additional capital in the future, which could lead to dilution for existing shareholders.
Recent events, as reflected in the financial data, show a continued pattern of losses and negative cash flows. The company's financial statements do not indicate any recent significant events or strategic initiatives that could alter its current trajectory. The absence of positive cash flows and the high price-to-revenue ratio of 1941.39 suggest that the market may be valuing the company based on future expectations rather than current performance.
- The company has a strong liquidity position with a high current ratio and significant cash reserves.
- Profitability is severely underperforming, with negative returns on equity and assets.
- The company's capital structure is equity-heavy, with minimal debt.
- The company is not generating positive cash flows, which could limit its ability to fund growth.
- There are no immediate liquidity or dilution risks, but the financial performance raises concerns about long-term sustainability.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 6483.TWO Market data — financials · 2026-05-27